Predictive Oncology (NASDAQ:POAI) Stock Price Crosses Below 200-Day Moving Average of $4.26

Posted by Defense World Staff on Oct 20th, 2023

Predictive Oncology Inc. (NASDAQ:POAI – Get Free Report) shares passed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $4.26 and traded as low as $3.53. Predictive Oncology shares last traded at $3.60, with a volume of 14,695 shares trading hands.

Predictive Oncology Trading Down 1.4 %

The firm has a 50 day simple moving average of $3.84 and a 200 day simple moving average of $4.26. The firm has a market capitalization of $14.51 million, a PE ratio of -0.74 and a beta of 1.59.

Predictive Oncology (NASDAQ:POAI – Get Free Report) last issued its earnings results on Thursday, August 10th. The medical instruments supplier reported ($0.95) EPS for the quarter. Predictive Oncology had a negative net margin of 1,246.52% and a negative return on equity of 90.72%. The business had revenue of $0.49 million for the quarter.

Insider Buying and Selling at Predictive Oncology

In other news, Director Charles Lee Sr Nuzum, Sr. sold 10,000 shares of the firm’s stock in a transaction on Monday, September 25th. The stock was sold at an average price of $3.04, for a total value of $30,400.00. Following the transaction, the director now directly owns 24,033 shares in the company, valued at approximately $73,060.32. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 2.26% of the company’s stock.

Hedge Funds Weigh In On Predictive Oncology

Institutional investors and hedge funds have recently modified their holdings of the company. Charles Schwab Investment Management Inc. purchased a new position in shares of Predictive Oncology in the 1st quarter worth $54,000. Virtu Financial LLC purchased a new position in shares of Predictive Oncology in the 1st quarter worth $66,000. Citadel Advisors LLC purchased a new position in shares of Predictive Oncology in the 3rd quarter worth $65,000. Renaissance Technologies LLC lifted its position in Predictive Oncology by 26.9% during the fourth quarter. Renaissance Technologies LLC now owns 302,724 shares of the medical instruments supplier’s stock valued at $93,000 after purchasing an additional 64,261 shares in the last quarter. Finally, RB Capital Management LLC lifted its position in Predictive Oncology by 161.2% during the first quarter. RB Capital Management LLC now owns 416,693 shares of the medical instruments supplier’s stock valued at $136,000 after purchasing an additional 257,193 shares in the last quarter. 6.03% of the stock is currently owned by hedge funds and other institutional investors.

About Predictive Oncology

(Get Free Report)

Predictive Oncology Inc operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples.